Caribou’s off-the-shelf CAR-T therapy shows hints of durability in early cut of data 

Cari­bou Bio­sciences shared an ear­ly cut of da­ta Thurs­day af­ter­noon that sug­gests its off-the shelf CAR-T ther­a­py for pa­tients with B cell lym­phoma could ri­val cur­rent­ly ap­proved CAR-T treat­ments.

In 16 pa­tients, sev­en were still in com­plete re­mis­sion six months af­ter re­ceiv­ing Cari­bou’s off-the-shelf CAR-T treat­ment, which is made from donor cells as op­posed to a pa­tient’s own cells like cur­rent­ly avail­able CAR-T ther­a­pies are. The first pa­tient treat­ed in the Phase I clin­i­cal tri­al, known as ANTLER, has been in com­plete re­mis­sion for two years.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN